The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.
Study Type
OBSERVATIONAL
Enrollment
50
Oral solution
United Biosource LLC
Morgantown, West Virginia, United States
RECRUITINGVivantes Humboldt-Klinikum Klinik für Neurologie
Berlin, Germany
RECRUITINGRate of MCM
Rate of Major congenital malformation (MCM) identified in the developing neonate and infant through 12 months of age
Time frame: Up to 12 months post birth
Rate of pregnancy outcomes
Rate of the following pregnancy outcomes: 1. Spontaneous abortion 2. Elective or therapeutic abortion 3. Fetal death/stillbirth 4. Molar or ectopic pregnancy 5. Preterm delivery 6. Live birth
Time frame: Up to 10 months gestation
Rate of other events of interest in the developing neonate and infant
Rate of the following other events of interest in the developing neonate and infant: 1. Hospitalizations for serious illness 2. Medications 3. Growth and development milestones 4. Neonatal or infant mortality 5. Inherited epilepsy syndrome
Time frame: Up to 12 months post birth
Rate of maternal complications during pregnancy
Rate of the following maternal complications during pregnancy: 1. Premature rupture of membranes (PROM) 2. Pre-eclampsia 3. Severe pregnancy-induced hypertension 4. Proteinuria 5. Gestational diabetes 6. Intrauterine growth restriction (IUGR) 7. Measures of fetal growth deficiency (small for gestational age)
Time frame: Up to 10 months gestation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.